MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts To Regulate Diabetic Stem Cells

MARIETTA, Ga., Aug. 26, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the …

[Read the full article here]

Comments are closed.